Millions of people with knee osteoarthritis live with daily pain and stiffness that erode their ability to walk, climb stairs, or sleep through the night. For many, the only definitive fix has been total knee replacement, a major surgery with months of recovery. Now, five-year data from randomized controlled trials show that targeted injections of sprifermin and platelet-rich plasma produced sustained pain relief and functional improvement years after treatment, raising the question of whether some patients can delay or avoid the operating room altogether.
Why five-year injection data shift the calculus for knee osteoarthritis
The standard toolkit for managing knee osteoarthritis before surgery has long been limited to physical therapy, anti-inflammatory drugs, corticosteroid shots, and hyaluronic acid injections. Each offers temporary symptom control, but none has shown durable structural benefit in cartilage preservation across multiple years. That gap is what makes the latest trial results significant: two distinct injection therapies now have randomized, controlled evidence stretching to five years or beyond.
Sprifermin, a recombinant human fibroblast growth factor 18, was tested in the FORWARD study, a large, double-blind trial that tracked patients for five years after intra-articular injection. In this trial, patients received different dosing regimens of sprifermin or placebo and then underwent serial MRI scans and clinical assessments over a prolonged follow-up. The investigators reported that treated knees showed increased cartilage thickness on MRI compared with placebo, and those structural gains persisted through the full five-year window. The study, available through a detailed trial report, also followed patient-reported WOMAC scores for pain and function, allowing researchers to examine whether cartilage changes translated into symptom relief.
The dual focus on imaging and symptoms matters because structural preservation alone does not help patients unless it results in less pain and better movement. In FORWARD, symptomatic outcomes generally favored sprifermin in specific subgroups, particularly patients with more advanced baseline cartilage loss, although the differences were more modest and variable than the MRI findings. Even so, the durability of the cartilage effect years after dosing stopped suggests that a short course of injections might alter the long-term trajectory of joint degeneration rather than just masking pain.
Separately, a prospective cohort study in patients with knee osteoarthritis found that the rate of cartilage loss over a two-year interval predicted which individuals were more likely to undergo total knee arthroplasty later on. In other words, faster early thinning of cartilage was associated with a higher probability of eventual replacement surgery. That observation creates a logical chain: if an injection slows cartilage degradation early, patients who respond may face a lower probability of needing replacement surgery years later. No randomized trial has yet confirmed this connection in a head-to-head comparison of injection-treated patients versus standard care through eight or more years of follow-up, but the biological rationale is strong enough to drive ongoing research.
Platelet-rich plasma trials extend the evidence to 60 months
Sprifermin is not the only injection therapy with long-duration data. Platelet-rich plasma, or PRP, is prepared by drawing a patient’s blood, spinning it in a centrifuge, and injecting the concentrated platelet fraction back into the joint. Platelets release growth factors and signaling molecules that may modulate inflammation and support tissue repair. Unlike sprifermin, which is an engineered protein, PRP is autologous and has been used in various musculoskeletal conditions, though protocols differ widely.
A double-blind randomized controlled trial compared PRP with hyaluronic acid injections in people with symptomatic knee osteoarthritis and reported outcomes at approximately 64 months of follow-up. In this study, participants received a series of injections and were then monitored for more than five years using standardized clinical scales. At the final visit, patients in the PRP group had superior scores on the IKDC subjective knee evaluation compared with those who received hyaluronic acid. The authors concluded that PRP provided more durable clinical benefit than the active comparator, a finding that is particularly notable because hyaluronic acid is already a widely used injection in orthopedic practice. Full details of the methodology and results are available in the published PRP versus hyaluronic acid trial.
A second prospective, multicenter, double-blind study added sham-controlled rigor. In that trial, patients were randomized to receive either intra-articular PRP or saline injections designed to mimic the procedure without delivering platelets. Participants were followed for up to 60 months, with repeated assessments using WOMAC pain and function scores. Across multiple time points, including the five-year mark, those treated with PRP reported lower pain and better function than the sham group. Because knee injections are known to carry a substantial placebo effect, the fact that PRP outperformed saline over such an extended period is clinically meaningful. The design and long-term outcomes of this work are summarized in a comprehensive sham-controlled PRP study.
Taken together, these trials establish that at least two injection approaches can produce measurable, patient-reported benefits that persist for years rather than weeks or months. The FORWARD study contributes structural cartilage data and hints at symptom improvement. The PRP trials contribute robust pain and functional data against both active and sham comparators, extending out to roughly five years. No single trial yet combines all of these endpoints in one patient population, which limits direct comparison between sprifermin and PRP and leaves open the question of which patients are best suited to each option.
Gaps in the evidence and what patients should watch for next
The trial results are encouraging, but several questions remain open. First, none of these studies was designed or powered to measure whether injection therapy actually reduces the rate of total knee replacement over a decade or more. The cartilage-loss predictor study established a statistical link between early structural decline and later surgery, yet no randomized trial has connected injection-driven cartilage preservation to a verified reduction in arthroplasty rates. That connection is therefore a plausible hypothesis rather than a proven outcome, and it will require long-term follow-up in large cohorts to test directly.
Second, real-world durability may differ from trial conditions. The FORWARD study and the PRP trials enrolled carefully selected patients, excluded many common comorbidities, and administered injections under standardized protocols. In everyday practice, patients may have more advanced disease, variable alignment issues, or inconsistent adherence to physical therapy and weight management. Data on how often patients outside of research settings receive repeat injections, how benefits evolve after the five-year mark, and whether outcomes differ by age, body mass index, or activity level are not yet available from large registries or insurance claims analyses.
Third, cost and access remain unresolved. PRP preparation techniques vary across clinics, leading to differences in platelet concentration and the presence of white blood cells. These technical details may influence both efficacy and side effects, but they are not standardized, and most payers do not cover PRP for knee osteoarthritis. Sprifermin, meanwhile, is still an investigational product rather than an approved therapy, limiting access to clinical trials. Until regulators review the full safety and efficacy data, clinicians and patients will not know how it will be labeled, priced, or reimbursed.
For patients considering their options today, these limitations mean that five-year injection data should be viewed as an important signal, not a guarantee. People with moderate knee osteoarthritis who are trying to postpone joint replacement may reasonably ask their clinicians whether they are candidates for PRP, recognizing that out-of-pocket costs can be substantial and that protocols differ. Those with earlier disease or rapidly progressing cartilage loss might eventually benefit from disease-modifying agents like sprifermin if and when they become available, but at present such therapies remain within the research domain.
Future studies will need to address several practical questions: which imaging or blood biomarkers best identify likely responders; how injection timing and dosing influence long-term outcomes; whether combining injections with targeted exercise, bracing, or weight loss produces additive benefits; and, most critically, whether any of these strategies meaningfully lower the lifetime risk of total knee replacement. Until those answers emerge, the new five-year data mark an important step toward disease modification in knee osteoarthritis, but not yet a replacement for surgery when joints are severely damaged.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
